+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the Enzeavour Pancreatic Cancer assay as a screening tool for pancreatic cancer in asymptomatic adults in Japan. This nationwide, multicenter, prospective, single-arm feasibility study aims to assess the detection rate and positive predictive value of this blood-based test in routine health checkups and cancer screening programs. Pancreatic cancer is often diagnosed late, and this study seeks to develop an effective population-based screening strategy. Participants will have blood samples collected during routine health checkups or organized cancer screenings. The Enzeavour assay measures the activity of three specific enzymes at a single-molecule level and combines four biomarkers into a composite score. Those with an Enzeavour Score above 0.369 will be referred for further diagnostic imaging such as MRCP, EUS, or contrast-enhanced CT as needed. This diagnostic work-up follows the initial screening result. Throughout the study, which follows participants for 12 months after the blood draw, researchers will monitor pancreatic cancer detection rates and the assays positive predictive value. Participants will be evaluated through blood tests and any indicated diagnostic imaging. The study will include approximately 10,000 adults and aims to provide real-world data for planning future trials. The total duration of participation varies based on follow-up needs.

Age: 20Years +All GendersPhase Not Applicable
69 locations
O

Actively Recruiting

This research observes patients with BRAF V600E mutation-positive unresectable advanced or recurrent solid tumors, excluding colorectal cancer, to monitor the safety and effectiveness of dabrafenib and trametinib. It is a prospective, multicenter, single-arm, non-interventional observational study that collects real-world data under current medical practices. The study is conducted using an electronic data capture system and aims to gather long-term information especially in pediatric patients. Participants receive dabrafenib and trametinib as prescribed according to the Japanese Package Insert without treatment assignment by the study. Adult patients are observed for one year after starting treatment, while pediatric patients are followed for up to eight years regardless of whether they continue treatment, to collect extensive safety and response data during the reexamination period. The study aims to include approximately 65 adults and about 20 pediatric patients. During the study, researchers collect data on adverse events related to skeletal and sexual maturation in pediatric patients, overall response rate in adults, progression-free survival, changes in height and weight, and other safety outcomes. Data collection occurs throughout the observation periods for both adult and pediatric patients. The study is sponsored by Novartis Pharmaceuticals and is designed to provide important long-term safety and effectiveness information on these medications used in routine care.

Age: 6Years - 99YearsAll Genders
70 locations